Valsts: Īrija
Valoda: angļu
Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)
Loratadine
Azure Pharmaceuticals Ltd
R06AX13
Loratadine
10 milligram(s)
Tablet
loratadine
Not marketed
2021-04-23
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LORATADINE 10 MG TABLETS loratadine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor, pharmacist, or nurse has told you. Keep this leaflet. You may need to read it again. Ask your pharmacist if you need more information or advice. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. You must talk to a doctor if you do not feel better, if you feel worse or if your symptoms change. See section 4. WHAT IS IN THIS LEAFLET 1. What Loratadine Tablets are and what they are used for _2._ _ _ What you need to know before you take Loratadine Tablets _ _ _3._ _ _ How to take Loratadine Tablets _ _ 4. Possible side effects _5._ _ _ How to store Loratadine Tablets _ _ 6. Contents of the pack and other information 1. WHAT LORATADINE TABLETS ARE AND WHAT THEY ARE USED FOR The full name of your medicine is Loratadine 10 mg Tablets. WHAT LORATADINE TABLETS ARE Loratadine Tablets contain the active substance loratadine which belongs to a class of medicines called “antihistamines”. HOW LORATADINE TABLETS WORK Loratadine Tablets help to reduce your allergy symptoms by stopping the effects of a substance called “histamine”, which is produced in the body when you are allergic to something. WHEN LORATADINE TABLETS SHOULD BE TAKEN Loratadine Tablets relieves symptoms associated with allergic rhinitis (for example, hay fever), such as sneezing, runny or itchy nose, and burning or itchy eyes. Loratadine Tablets may also be used to help relieve symptoms of urticaria (itching and redness) which is often known as hives or nettle rash. The effect of Loratadine Tablets will last a whole day and should help you to continue your normal daily activities and sleep. You must talk to a doctor if you do not feel better or if you f Izlasiet visu dokumentu
Health Products Regulatory Authority 23 April 2021 CRN008WKS Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Loratadine 10 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg Loratadine. Excipients with known effect: The quantity of lactose monohydrate is 35.00 mg. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablets White to off white uncoated tablets, breakline on one side and 'L' embossed on other side. The score line of the tablet is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Loratadine 10 mg tablets are indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY _ADULTS, INCLUDING THE ELDERLY, AND CHILDREN 6 YEARS OF AGE AND OLDER WITH A BODYWEIGHT GREATER THAN 30 KG:_ One 10 mg tablet once daily. For appropriate dosing in children younger than 6 years or with body weight of 30 kg or less, there are other formulations more suitable. _CHILDREN UNDER 2 YEARS OF AGE:_ Safety and efficacy of Loratadine 10 mg tablets in children under 2 years of age has not been established. No data are available. _Patients with hepatic impairment_ Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of Loratadine. An initial dose of 10 mg every other day is recommended for adults and children weighing more than 30 kg. _Patients with renal impairment_ No dosage adjustments are required in the elderly or in patients with renal insufficiency. _Elderly_ No dosage adjustments are required in the elderly. METHOD OF ADMINISTRATION Oral use. The tablet may be taken without regard to mealtime. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Health Products Regulatory Authority 23 April 2021 CRN008WKS Page 2 of 6 4.4 SPECIAL WARNINGS AND PRECAU Izlasiet visu dokumentu